<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-title-group><journal-title>eBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38917512</article-id><article-id pub-id-type="pmc">PMC467072</article-id><article-id pub-id-type="pii">S2352-3964(24)00256-1</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2024.105221</article-id><article-id pub-id-type="publisher-id">105221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Optimal use of &#x003b2;-lactams in neonates: machine learning-based clinical decision support system</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Tang</surname><given-names>Bo-Hao</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Yao</surname><given-names>Bu-Fan</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Zhang</surname><given-names>Xin-Fang</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Fu</surname><given-names>Shu-Meng</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Hao</surname><given-names>Guo-Xiang</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Zhou</surname><given-names>Yue</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Sun</surname><given-names>De-Qing</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Liu</surname><given-names>Gang</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>van den Anker</surname><given-names>John</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Wu</surname><given-names>Yue-E</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Zheng</surname><given-names>Yi</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Zhao</surname><given-names>Wei</given-names></name><email>zhao4wei2@hotmail.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff7" ref-type="aff">g</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China</aff><aff id="aff2"><label>b</label>Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China</aff><aff id="aff3"><label>c</label>Nephrology Research Institute of Shandong University, The Second Hospital of Shandong University, Jinan, China</aff><aff id="aff4"><label>d</label>Division of Clinical Pharmacology, Children&#x02019;s National Hospital, Washington, DC, USA</aff><aff id="aff5"><label>e</label>Departments of Pediatrics, Pharmacology &#x00026; Physiology, Genomics &#x00026; Precision Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA</aff><aff id="aff6"><label>f</label>Department of Pediatric Pharmacology and Pharmacometrics, University of Basel Children&#x02019;s Hospital, Basel, Switzerland</aff><aff id="aff7"><label>g</label>NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Shandong University, Jinan, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China <email>zhao4wei2@hotmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>24</day><month>6</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>7</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>24</day><month>6</month><year>2024</year></pub-date><volume>105</volume><elocation-id>105221</elocation-id><history><date date-type="received"><day>1</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>29</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Author(s)</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><sec><title>Background</title><p>Accurate prediction of the optimal dose for &#x003b2;-lactam antibiotics in neonatal sepsis is challenging. We aimed to evaluate whether a reliable clinical decision support system (CDSS) based on machine learning (ML) can assist clinicians in making optimal dose selections.</p></sec><sec><title>Methods</title><p>Five &#x003b2;-lactam antibiotics (amoxicillin, ceftazidime, cefotaxime, meropenem and latamoxef), commonly used to treat neonatal sepsis, were selected. The CDSS was constructed by incorporating the drug, patient, dosage, pharmacodynamic, and microbiological factors. The CatBoost ML algorithm was used to build the CDSS. Real-world studies were used to evaluate the CDSS performance. Virtual trials were used to compare the CDSS-optimized doses with guideline-recommended doses.</p></sec><sec><title>Findings</title><p>For a specific drug, by entering the patient characteristics and pharmacodynamic (PD) target (50%/70%/100% fraction of time that the free drug concentration is above the minimal inhibitory concentration [fT&#x000a0;&#x0003e;&#x000a0;MIC]), the CDSS can determine whether the planned dosing regimen will achieve the PD target and suggest an optimal dose. The prediction accuracy of all five drugs was &#x0003e;80.0% in the real-world validation. Compared with the PopPK model, the overall accuracy, precision, recall, and F1-Score improved by 10.7%, 22.1%, 64.2%, and 43.1%, respectively. Using the CDSS-optimized doses, the average probability of target concentration attainment increased by 58.2% compared to the guideline-recommended doses.</p></sec><sec><title>Interpretation</title><p>An ML-based CDSS was successfully constructed to assist clinicians in selecting optimal &#x003b2;-lactam antibiotic doses.</p></sec><sec><title>Funding</title><p>This work was supported by the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source>; <funding-source id="gs8">Distinguished Young and Middle-aged Scholar of Shandong University</funding-source>; <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source>.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Neonates</kwd><kwd>Individual treatment</kwd><kwd>Machine-learning</kwd><kwd>&#x003b2;-lactam antibiotics</kwd><kwd>Clinical decision support system</kwd></kwd-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1"><caption><title>Research in context</title></caption><sec id="dtbox1sec1"><title>Evidence before this study</title><p id="p0015">Various factors determine the optimal dose of &#x003b2;-lactam antibiotics in neonates: (a) Developmental/maturation factors; (b) Pathogen factors. (c) Pharmacodynamics target; (d) Drug type and dosage regimen. Traditional population-based methods, while quantifying these factors to some degree, have problems with prognostic precision and accuracy.</p></sec><sec id="dtbox1sec2"><title>Added value of this study</title><p id="p0020">A machine learning-based clinical decision support system (CDSS) was successfully constructed to assist clinicians in making optimal dose selections for &#x003b2;-lactam antibiotics. The prediction accuracy of all five drugs was &#x0003e;80.0% in the real-world validation.</p></sec><sec id="dtbox1sec3"><title>Implications of all the available evidence</title><p id="p0025">For a specific drug, by entering patient characteristics (current weight, birth weight, gestational age, postnatal age, postmenstrual age, serum creatinine) and the PD target (50%/70%/100% fT&#x000a0;&#x0003e;&#x000a0;MIC [fraction of time that the free concentration is above the MIC]), the CDSS can determine whether the planned dosing regimen will achieve the PD target and suggest an optimal dose.</p></sec></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">Neonatal sepsis is an invasive disease with high rates of morbidity and mortality.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> &#x003b2;-lactam antibiotics are among the most frequently prescribed antibiotics for the treatment of neonatal sepsis.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> However, accurately predicting of the optimal dose of these antibiotics is difficult.</p><p id="p0035">Various factors determine the optimal dose of &#x003b2;-lactam antibiotics. First, the rapid physiological changes and specific pathophysiology in neonates result in extensive intra- and inter-subject variability in drug disposition and clinical responses, respectively. Second, infectious pathogens and their corresponding MICs are the basis for selecting an appropriate antibiotic therapy. However, it is sometimes difficult to obtain positive cultures and/or antimicrobial susceptibility test results for bacteria that cause sepsis in neonates. Thirdly, the pharmacodynamics (PD) target of time-dependent &#x003b2;-lactam antibiotics is the fraction of the time during which the free antibiotic concentration remains above the minimum inhibitory concentration of the targeted pathogens (%fT&#x000a0;&#x0003e;&#x000a0;MIC).<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> However, the specific target PD value in neonates remains controversial. There is no generally accepted PD target; as in recent neonatal studies, the PD target ranges from 40% fT&#x000a0;&#x0003e;&#x000a0;MIC to 100% fT&#x000a0;&#x0003e;&#x000a0;4&#x02013;5 x MIC. Lastly, the type of &#x003b2;-lactam antibiotics and their dosage regimens selected for the treatment of neonatal sepsis vary between centers and regions.</p><p id="p0040">Although traditional population-based methods quantify these factors to some degree, there are problems with their prognostic precision and accuracy.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Therefore, a new advanced approach capable of integrating multiple factors is required to accurately prediction of individual optimal doses. In recent years, machine learning (ML) has become increasingly popular in clinical applications The mechanisms of ML are unique and sensitive to multiple factors and are now becoming the key to solving difficult problems.</p><p id="p0045">Thus, this study aimed to evaluate whether a clinical decision support system (CDSS) can be constructed based on ML integration of multiple factors to assist clinicians in optimal dose selection, using five beta-lactam antibiotics (ceftazidime, cefotaxime, meropenem, latamoxef, and amoxicillin) commonly used in the treatment of neonatal sepsis, as &#x0201c;proof of concept&#x0201d;.</p></sec><sec id="sec2"><title>Methods</title><p id="p0050">The methods of this study consisted of three steps: CDSS construction, external validation of the CDSS in real-world study, and CDSS-based dose optimization. A&#x000a0;schematic of this study was shown in <xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>.<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Diagram illustrating the construction, evaluation, optimization, and application of the clinical decision support system. CDSS: Clinical Decision Support System; PopPK: population pharmacokinetic; ML: machine learning; CL: clearance; V1: central volume of distribution; V2: peripheral volume of distribution; Q: inter-compartment clearance.</p></caption><graphic xlink:href="gr1"/></fig></p><sec id="sec2.1"><title>CDSS construction</title><p id="p0055">The CDSS was achieved through the construction of ML datasets and subsequent ML analysis to develop predictive models.</p><sec id="sec2.1.1"><title>ML dataset construction</title><p id="p0060">Information on neonates receiving antibacterial treatments from previous neonatal studies was used to establish a virtual neonate dataset.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref> The dataset included information on 2569 neonates. The mean (SD) values of current weight (CW) and postmenstrual age (PMA) were 2463 (1023) [range 450&#x02013;9370] g and 36.9 (4.43) [range 28.4&#x02013;48.0] weeks. Extremely preterm births (GA &#x0003c; 28 weeks) were excluded from the virtual dataset. Detailed patient information was shown in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Statistical information for virtual neonates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>n</th><th>Mean (SD)</th><th>Median (range)</th></tr></thead><tbody><tr><td>Patients characteristics</td><td align="char">2569</td><td/><td/></tr><tr><td>GA (weeks)</td><td/><td align="char">34.8 (4.34)</td><td align="char">35.3 (28.0&#x02013;43.4)</td></tr><tr><td>PNA (days)</td><td/><td align="char">15.0 (13.6)</td><td align="char">11.0 (1.00&#x02013;91.0)</td></tr><tr><td>PMA (weeks)</td><td/><td align="char">36.9 (4.43)</td><td align="char">37.4 (28.4&#x02013;48.0)</td></tr><tr><td>CW (g)</td><td/><td align="char">2463 (1023)</td><td align="char">2400 (450&#x02013;9370)</td></tr><tr><td>BW (g)</td><td/><td align="char">2345 (828)</td><td align="char">2056 (1000&#x02013;4850)</td></tr><tr><td>CREA (&#x003bc;mol/L)</td><td/><td align="char">48.7 (28.6)</td><td align="char">45.0 (1.10&#x02013;518)</td></tr></tbody></table><table-wrap-foot><fn><p>CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine.</p></fn></table-wrap-foot></table-wrap></p><p id="p0065">For each of the five drugs, published population pharmacokinetic (PopPK) models were searched and selected that could cover the entire age range of the neonatal population. Based on the PopPK model, Monte Carlo simulations were performed for individual concentrations under different scenarios (see below) using the virtual neonatal dataset. In this study, considering the actual clinical medication scenarios, the following four aspects were considered in the setting of the simulation scenarios: (1) Drug categories. In this study, different categories of &#x003b2;-lactam antibiotics were selected for clinical use in neonates, including penicillins (amoxicillin), cephalosporins (ceftazidime and cefotaxime), carbapenems (meropenem) and oxacephalosporins (latamoxef). They are primarily eliminated by the kidneys via time-dependent bacterial killing mechanisms. In adults, the protein binding rates of ceftazidime, cefotaxime, meropenem, latamoxef, and amoxicillin were 10.0%, 40.0%, 2.0%, 52.0%, and 10.0%, respectively.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref> Because of the lack of data on protein binding in neonates, the adult values were used. The free concentration of a drug that is effective in the body is equal to the total drug concentration multiplied by the proportion that is not bound to the protein. (2) Patient Characteristics. The large dataset of virtual neonates covered the entire age range of neonates and young infants. Covariates reflecting the growth (size), renal maturity, and renal function of the neonates, that is, birth weight (BW), current weight (CW), gestational age at birth (GA), postmenstrual age (PMA), postnatal age (PNA), serum creatinine concentration (CREA), and albumin (ALB), were included in the dataset. (3) Dosage regimen. The dose range selected for the simulation set covered the drug's routine dosing regimens for neonates in clinical practice. The simulated dose ranges for ceftazidime, cefotaxime, meropenem, latamoxef, and amoxicillin were 20&#x02013;50, 20&#x02013;60, 10&#x02013;40, 15&#x02013;40, and 20&#x02013;50&#x000a0;mg/kg, respectively. During these simulations, the dose was increased from the lower limit of the range of 5 units to the upper limit. Two commonly used dosing frequencies in the clinical settings were selected: Q12h and Q8h. All five drugs were administered as a 30&#x000a0;min intravenous infusion. (4) Sampling time. The PD target values (%fT&#x000a0;&#x0003e;&#x000a0;MIC) of &#x003b2;-lactam antibiotics are still controversial. We selected three common PD targets, 50%, 70% and 100% fT&#x000a0;&#x0003e;&#x000a0;MIC. Therefore, we simulated the steady-state concentrations at 50%, 70%, and 100% dosing interval time points. The number of simulation scenarios was determined by multiplying the number of drug categories, patients, dosage regimens, and sampling times. For each virtual neonate in a simulation scenario, 1000 simulated concentrations were obtained from 1000 Monte Carlo simulations. The median concentration was then calculated and used as the final simulated concentration for each individual in the given scenario.</p><p id="p0070">After obtaining the simulated concentrations under different simulation scenarios, it was essential to use the pathogen MIC values of the pathogen to determine whether the concentrations were adequate (i.e., whether the simulated concentrations covered the MIC of the pathogen). Therefore, the choice of the MIC was crucial. This study investigated relevant studies to identify the common pathogens causing early-onset sepsis (EOS) and late-onset sepsis (LOS). The MIC values of these five antibacterial agents against pathogenic bacteria were determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) and other studies.<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref></p><p id="p0075">A new binary variable, &#x0201c;TAR&#x0201d;, was formed by comparing the simulated concentration with the pathogen MIC value to determine whether the individual concentration under different simulation scenarios met the target. If the simulated concentration met the target, then &#x0201c;TAR&#x0201d;&#x000a0;=&#x000a0;1; if it does not, then &#x0201c;TAR&#x0201d;&#x000a0;=&#x000a0;0. For example, if a virtual neonate was administered a dosing regimen of amoxicillin 20&#x000a0;mg/kg Q12h, the steady-state simulated concentration at the 50% dosing interval was 7&#x000a0;mg/L. If the corresponding pathogen MIC was 8&#x000a0;mg/L, the target was not met in the current situation, and &#x0201c;TAR&#x0201d;&#x000a0;=&#x000a0;0. &#x0201c;TAR&#x0201d; was used as a prediction target in building subsequent ML analysis.</p></sec><sec id="sec2.1.2"><title>ML analysis</title><p id="p0080">The binary variable &#x0201c;TAR&#x0201d; was used as a prediction target. The following potential predictors were included in the simulation scenarios mentioned above, the chosen drug, patient characteristics (BW, CW, PNA, PMA, GA, CREA, and ALB), dosage and frequency (Q12h/Q8h) of the chosen drug, and sampling time (50/70/100% dosing interval). The simulation dataset was divided into training (80.0%) and the test (20.0%) datasets. Five-fold nested cross-validation (NeCV) was applied to tune the hyper-parameters and evaluate the model performance. NeCV has gained widespread acceptance as &#x0201c;state-of-the-art&#x0201d; in the ML field as it is a (nearly) objective model assessment approach for predicting the genuine error.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The inner cross-validation selected the best hyper-parameters, and the performance of the model was assessed by the outer cross-validation, utilizing the best parameters from the inner cross-validation selection. Detailed information on the NeCV method used in this study was shown in <xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>.<fig id="fig2"><label>Fig.&#x000a0;2</label><caption><p>Nested cross-validation method used in this study.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0085">Categorical Boosting (CatBoost) was used for ML analysis.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> CatBoost is a fast, scalable, and high-performance algorithm for gradient boosting of decision trees.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> CatBoost implements oblivious decision trees, thereby restricting the features split per level to one, which helps reduce the prediction time. It effectively handled categorical features using ordered target statistics. The accuracy, precision, recall, and balanced score (F1-Score) were calculated to evaluate the predictive performance. The Shapley additive explanations (SHAP) were calculated and visualized to evaluate the contribution of each covariate.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> All the ML analyses were implemented in Anaconda using Python 3.7. The final ML prediction models for the five &#x003b2;-lactam antibiotics were packaged and integrated to form the CDSS.</p></sec></sec><sec id="sec2.2"><title>External validation of CDSS in real-world study</title><sec id="sec2.2.1"><title>Evaluation of CDSS predictive performance</title><p id="p0090">Real-world data were obtained from five hospitals. Neonates receiving anti-infective treatment with the five previously mentioned &#x003b2;-lactams were included. Neonatal information was collected based on the parameters of the trained ML model, such as drug categories, patient characteristics, dosage regimen (dosage and frequency), sampling time, and individual concentrations.</p><p id="p0095">The real target (i.e., &#x0201c;TAR&#x0201d;) of the real-world validation dataset was set based on whether the actual individual concentrations exceeded the MIC. It can be categorized into two situations. (1) Standard scenario: Individual steady-state concentrations were sampled at the target time point (50% or 70% or 100% dosing interval&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;h). It can directly determine whether the concentration at the target time point has achieved the target. (2) Inference scenario: If the sampling time point for individual steady-state concentration was before the target time point, and the concentration was less than the MIC value, then &#x0201c;TAR&#x0201d;&#x000a0;=&#x000a0;0; however, if the sampling time point for individual concentrations was after the target time point, and the concentration was greater than the MIC value, then &#x0201c;TAR&#x0201d;&#x000a0;=&#x000a0;1.</p><p id="p0100">Using the CDSS, a prediction was made regarding whether individual concentrations would meet the target under the actual dosing regimen. The results were compared with a real target of a real-world validation dataset, and the prediction accuracy, precision, recall, and F1-Score were calculated.</p></sec><sec id="sec2.2.2"><title>Predictive performance of CDSS compared to the PopPK model</title><p id="p0105">In this section, we compared the predictive performances of the CDSS and PopPK models. For the PopPK model (the PopPK model selected for each drug was the same as that in Section 2.1), individual concentrations were predicted based on typical population estimates of the model and all available patient covariates and dosing information. The prediction accuracy, precision, recall, and F1-Score were calculated as described previously, and the results were compared with those of the CDSS.</p></sec></sec><sec id="sec2.3"><title>CDSS-based dose optimization</title><p id="p0110">Virtual trials were used to compare the CDSS-optimized doses with the guideline-recommended doses. The CDSS-optimized dose was obtained by optimizing the&#x000a0;individual dose using the CDSS. The sources of the guideline-recommended doses were as follows: (1) Manual of Childhood Infections: The Blue Book (BLUE)<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>; (2) British National Formulary for Children (BNFC)<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>; and (3) Food and Drug Administration label (FDAL).</p><p id="p0115">Virtual trials were conducted using an external validation dataset. Monte Carlo simulations were conducted based on the PK parameters of the published PopPK model, and 1000 simulations were performed for the CDSS-optimized and guideline-recommended dose regimens. The individual steady-state concentrations were predicted for each simulated virtual neonate at 70% of the dosing interval. The probability of target concentration attainment (PTA) was calculated as the percentage of virtual neonates meeting the PD target (steady-state individual concentrations in the range of 1&#x02013;8&#x000a0;&#x000d7;&#x000a0;MIC, where 8&#x000a0;&#x000d7;&#x000a0;MIC was used as the toxicity threshold<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>).</p><sec id="sec2.3.1"><title>Ethic</title><p id="p0120">All the data were obtained from previous studies. These studies were approved by the institutional ethics committees of different hospitals: Beijing Children&#x02019;s Hospital (2020-k-163), Beijing Obstetrics and Gynecology Hospital (2020-KY-045-01), Shandong Province Qianfoshan Hospital (2017S021), Children&#x02019;s Hospital of Hebei Province (No.127), and Affiliated Hospital of Xuzhou Medical University (XYFY2019-KL194-01). Parental informed consent to participate was obtained for each newborn.</p></sec><sec id="sec2.3.2"><title>Role of funders</title><p id="p0125">The funders played no role in the study design, data collection, data analysis, data interpretation, and paper writing.</p></sec></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>CDSS construction</title><p id="p0130">Five published PopPK models (corresponding to five drugs) covering the entire age range of neonates and young infants were selected for the simulation process.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> The PopPK mathematical model is described in detail in <xref rid="appsec1" ref-type="sec">Supplementary Material S1</xref>. The characteristics of the neonates enrolled for modeling and the mathematical models of the selected PopPK models for the five drugs were presented in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Material S1</xref>.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Patient characteristics extracted from the published studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Ceftazidime</th><th>Cefotaxime</th><th>Meropenem</th><th>Latamoxef</th><th>Amoxicillin</th></tr></thead><tbody><tr><td>Patients</td><td>146</td><td>100</td><td>188</td><td>128</td><td>187</td></tr><tr><td>Samples</td><td>203</td><td>185</td><td>780</td><td>165</td><td>224</td></tr><tr><td>BW (kg)</td><td>3.00 (0.740&#x02013;4.65)</td><td>1.42 (0.512&#x02013;3.99)</td><td>1.08 (0.330&#x02013;4.77)</td><td>3.10 (1.01&#x02013;4.58)</td><td>3.05 (1.04&#x02013;4.60)</td></tr><tr><td>CW (kg)</td><td>3.08 (0.900&#x02013;4.50)</td><td>1.65 (0.530&#x02013;4.20)</td><td>/</td><td>3.22 (1.00&#x02013;4.60)</td><td>3.21 (1.06&#x02013;4.58)</td></tr><tr><td>GA (weeks)</td><td>38.6 (26.0&#x02013;43.4)</td><td>31.5 (23.0&#x02013;42.0)</td><td>28.0 (23.0&#x02013;40.0)</td><td>38.3 (27.3&#x02013;41.4)</td><td>38.1 (28.3&#x02013;41.4)</td></tr><tr><td>PNA (days)</td><td>11.0 (1.00&#x02013;81.0)</td><td>9.0 (1.00&#x02013;69.0)</td><td>21.0 (1.00&#x02013;92.0)</td><td>8.00 (1.00&#x02013;54.0)</td><td>7.00 (1.00&#x02013;37.0)</td></tr><tr><td>PMA (weeks)</td><td>40.3 (26.1&#x02013;47.4)</td><td>33.0 (25.0&#x02013;44.0)</td><td>33.0 (24.0&#x02013;51.0)</td><td>39.7 (28.4&#x02013;46.1)</td><td>39.0 (28.4&#x02013;46.3)</td></tr><tr><td>CREA (&#x003bc;mol/L)</td><td>33.8 (8.0&#x02013;201.3)</td><td>44.0 (13.0&#x02013;226.0)</td><td>/</td><td>/</td><td>38.0 (8.80&#x02013;156)</td></tr><tr><td>ALB (g/L)</td><td>31.7 (18.4&#x02013;42.0)</td><td>27.0 (17.0&#x02013;38.0)</td><td>23 (/)</td><td>/</td><td>/</td></tr></tbody></table><table-wrap-foot><fn id="tspara0025"><p>Patient demographic characteristics and clearance values are presented as median (range).</p></fn><fn id="tspara0030"><p>CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine; ALB: albumin.</p></fn></table-wrap-foot></table-wrap></p><p id="p0135">According to national and international references, <italic>Escherichia coli, Klebsiella pneumoniae, Group B Streptococcus, Staphylococcus aureus, and Coagulase-negative Staphylococcus</italic> are the most common pathogens that cause neonatal sepsis.<xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref> The MIC values of the five drugs for different pathogens were presented in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>. Then, 8, 8, 8, 4, and 4&#x000a0;mg/L were selected as the final MICs for amoxicillin, ceftazidime, cefotaxime, meropenem, and latamoxef, respectively, to identify the most common pathogens. Thus, these selected MICs were used to determine whether the individual concentrations simulated under different scenarios met the PD targets.<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>The MIC values of different pathogens for the five drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="5">MIC values of five drugs<hr/></th></tr><tr><th>AMX</th><th>CTD</th><th>COX</th><th>MERO</th><th>MOX</th></tr></thead><tbody><tr><td>Pathogens</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;<italic>E.coli</italic></td><td align="char">8</td><td>&#x0003c;4/8</td><td>1</td><td align="char">&#x0003c;4</td><td>0.12</td></tr><tr><td>&#x000a0;<italic>KP</italic></td><td align="char">8</td><td>&#x0003c;4/8</td><td>1</td><td align="char">&#x0003c;4</td><td>1</td></tr><tr><td>&#x000a0;<italic>CoNS</italic></td><td>-<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>-<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>4</td><td align="char">4</td><td>4</td></tr><tr><td>&#x000a0;<italic>STA</italic></td><td>-<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>-<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>4/8</td><td align="char">4</td><td>4</td></tr><tr><td>&#x000a0;<italic>GBS</italic></td><td align="char">0.25</td><td>-<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td>0.5</td><td align="char">0.25</td><td>-<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td></tr></tbody></table><table-wrap-foot><fn><p><italic>E.coli</italic>: <italic>Escherichia coli</italic>; <italic>KP</italic>: <italic>Klebsiella pneumoniae</italic>; <italic>CoNS</italic>: <italic>Coagulase-negative Staphylococcus</italic>; <italic>STA</italic>: <italic>Staphylococcus aureus</italic>; <italic>GBS</italic>: <italic>Group B Staphylococcus</italic>. AMX: amoxicillin; CTD: ceftazidime; COX: cefotaxime; MERO: meropenem; MOX: latamoxef.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0010">Coagulase-negative <italic>Staphylococcus, Staphylococcus aureus</italic>, and <italic>Group B Staphylococcus</italic> were usually resistant to ceftazidime, amoxicillin.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0015">: Not found.</p></fn></table-wrap-foot></table-wrap></p><p id="p0140">Using the CatBoost algorithm, the prediction accuracy, accuracy, recall, and F1-Score for all five drugs exceeded 98.0%. Machine learning analysis was applied separately to each of the five drugs, and the results were presented in <xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>. Different drugs have different covariate importance rankings. For ceftazidime, cefotaxime, and latamoxef, the dosage regimen (dose and frequency) and PD target were the three most important covariates, followed by neonatal maturation and size covariates. For meropenem, PD target, frequency and PMA were the most important three covariates. For amoxicillin, PMA, frequency and dose were the most important three covariates. CREA was almost tricky to help prediction, except for meropenem. The relative importance of the covariates influencing the predictions for each of the five drugs was presented in <xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>.<table-wrap position="float" id="tbl4"><label>Table&#x000a0;4</label><caption><p>Machine learning analysis results (Test set and Real-world validation data results).</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>AMX</th><th>CTD</th><th>COX</th><th>MERO</th><th>MOX</th></tr></thead><tbody><tr><td>Test set results</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;ML</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Accuracy (%)</td><td align="char">98.8</td><td align="char">98.9</td><td align="char">99.0</td><td align="char">98.7</td><td align="char">98.7</td></tr><tr><td>&#x000a0;Precision (%)</td><td align="char">98.5</td><td align="char">99.2</td><td align="char">99.3</td><td align="char">98.9</td><td align="char">98.9</td></tr><tr><td>&#x000a0;Recall (%)</td><td align="char">98.2</td><td align="char">99.3</td><td align="char">99.4</td><td align="char">99.0</td><td align="char">99.1</td></tr><tr><td>&#x000a0;F1 score (%)</td><td align="char">98.3</td><td align="char">99.3</td><td align="char">99.3</td><td align="char">99.0</td><td align="char">99.0</td></tr><tr><td colspan="2">Real world validation data results</td><td/><td/><td/><td/></tr><tr><td colspan="2">&#x000a0;ML (CDSS)</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Accuracy (%)</td><td align="char">96.2</td><td align="char">84.1</td><td align="char">90.4</td><td align="char">83.1</td><td align="char">88.5</td></tr><tr><td>&#x000a0;Precision (%)</td><td align="char">82.4</td><td align="char">85.5</td><td align="char">93.8</td><td align="char">86.5</td><td align="char">93.4</td></tr><tr><td>&#x000a0;Recall (%)</td><td align="char">82.4</td><td align="char">87.7</td><td align="char">95.8</td><td align="char">86.5</td><td align="char">89.5</td></tr><tr><td>&#x000a0;F1score (%)</td><td align="char">82.4</td><td align="char">86.6</td><td align="char">94.8</td><td align="char">86.5</td><td align="char">91.4</td></tr><tr><td>&#x000a0;PopPK</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Accuracy (%)</td><td align="char">87.9</td><td align="char">82.6</td><td align="char">77.9</td><td align="char">73.5</td><td align="char">78.4</td></tr><tr><td>&#x000a0;Precision (%)</td><td align="char">40.0</td><td align="char">85.2</td><td align="char">90.5</td><td align="char">89.5</td><td align="char">90.1</td></tr><tr><td>&#x000a0;Recall (%)</td><td align="char">23.5</td><td align="char">85.2</td><td align="char">80.7</td><td align="char">65.4</td><td align="char">76.8</td></tr><tr><td>&#x000a0;F1score (%)</td><td align="char">29.6</td><td align="char">85.2</td><td align="char">85.4</td><td align="char">75.6</td><td align="char">83.0</td></tr></tbody></table><table-wrap-foot><fn><p>AMX: amoxicillin; CTD: ceftazidime; COX: cefotaxime, MERO: meropenem; MOX: latamoxef.</p></fn></table-wrap-foot></table-wrap><fig id="fig3"><label>Fig.&#x000a0;3</label><caption><p>SHAP results of model covariates. Each point represents a sample. A higher intensity of the red color indicates a more relevant covariate whereas a higher intensity of the blue color indicates a less relevant covariate. If most SHAP values of the red points are located in the area greater than 0, and most SHAP values of the blue points are located in the area less than 0, it means that the covariate has a positive correlation with the target variable and vice versa. BW: birth weight; CW: current weight; GA: gestational age at birth; PMA: postmenstrual age; PNA: postnatal age; CREA: Serum creatinine concentration; ALB: albumin. (A) Ceftazidime; (B) cefotaxime; (C) meropenem; (D) latamoxef; (E) amoxicillin.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec3.2"><title>External validation of CDSS in real-world study</title><sec id="sec3.2.1"><title>Predictive performance of CDSS</title><p id="p0145">In total, 621 blood samples from 621 patients were included in the validation dataset. The necessary information was collected based on the covariates of the final ML model, including GA, PMA, PNA, BW, CW, CREA, AMT, FRE, FT, and TAR (with the additional collection of ALB for meropenem). Demographic information, drug treatment details, and essential information for model predictions were summarized in <xref rid="tbl5" ref-type="table">Table&#x000a0;5</xref>.<table-wrap position="float" id="tbl5"><label>Table&#x000a0;5</label><caption><p>Information of the real-world validation dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Amoxicillin</th><th>Ceftazidime</th><th>Cefotaxime</th><th>Meropenem</th><th>Latamoxef</th></tr></thead><tbody><tr><td>Patient (samples)</td><td>157 (157)</td><td>138 (138)</td><td>104 (104)</td><td>83 (83)</td><td>139 (139)</td></tr><tr><td>&#x000a0;GA (weeks)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>38.0 (28.1&#x02013;41.3)</td><td>37.9 (26.0&#x02013;43.4)</td><td>32.0 (23.0&#x02013;42.0)</td><td>35.3 (26.3&#x02013;42.1)</td><td>37 (27.3&#x02013;41.1)</td></tr><tr><td>&#x000a0;PMA (weeks)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>38.9 (28.4&#x02013;44.1)</td><td>40.0 (26.1&#x02013;47.4)</td><td>34.2 (26.4&#x02013;44.4)</td><td>37.1 (25.6&#x02013;48.0)</td><td>38.3 (31.0&#x02013;44.1)</td></tr><tr><td>&#x000a0;PNA (days)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>7.0 (1.0&#x02013;37.0)</td><td>13.0 (1.0&#x02013;81.0)</td><td>8.5 (1.0&#x02013;108.0)</td><td>23.0 (4.0&#x02013;116.0)</td><td>7.0 (1.0&#x02013;54.0)</td></tr><tr><td>&#x000a0;BW (kg)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>3.0 (1.2&#x02013;4.2)</td><td>2.8 (0.7&#x02013;4.7)</td><td>2.7 (1.4&#x02013;3.5)</td><td>1.9 (0.5&#x02013;3.9)</td><td>2.7 (1.2&#x02013;4.1)</td></tr><tr><td>&#x000a0;CW (kg)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>3.2 (1.2&#x02013;4.3)</td><td>2.9 (0.9&#x02013;4.8)</td><td>1.9 (0.5&#x02013;4.2)</td><td>2.1 (1.1&#x02013;5.3)</td><td>2.7 (1.1&#x02013;4.2)</td></tr><tr><td>&#x000a0;CREA (&#x003bc;mol/L)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>36.0 (8.8&#x02013;167.9)</td><td>34.4 (8.0&#x02013;201.0)</td><td>45.0 (12.0&#x02013;226.0)</td><td>25.2 (1.3&#x02013;126.0)</td><td>41.0 (4.5&#x02013;103.0)</td></tr><tr><td>&#x000a0;ALB (g/L)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>/</td><td>/</td><td>/</td><td>2.3 (1.5&#x02013;4.5)</td><td>/</td></tr><tr><td>Treatment</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Dose (mg/dose)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>75.0 (25.0&#x02013;110.0)</td><td>90.0 (30.0&#x02013;140.0)</td><td>100 (28.0&#x02013;208.0)</td><td>55.0 (18.0&#x02013;150.0)</td><td>85.0 (40.0&#x02013;140.0)</td></tr><tr><td>&#x000a0;Dose (mg/kg/dose)<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td>23.7 (16.7&#x02013;32.1)</td><td>29.1 (21.2&#x02013;80.0)</td><td>49.5 (31.7&#x02013;105.0)</td><td>19.8 (8.80&#x02013;85.7)</td><td>30.0 (24.0&#x02013;56.1)</td></tr><tr><td>&#x000a0;FRE<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td>Q12h: 63.7%<break/>Q8h: 36.3%</td><td>Q12h: 60.1%<break/>Q8h: 39.9%</td><td>Q12h: 52.9%<break/>Q8h: 47.1%</td><td>Q12h: 28.9%<break/>Q8h: 71.1%</td><td>Q12h: 69.8%<break/>Q8h: 30.2%</td></tr><tr><td>&#x000a0;FT<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td>1: 13.4%<break/>2: 8.9%<break/>3: 77.7%</td><td>1: 58.7%<break/>2: 3.6%<break/>3: 37.7%</td><td>1: 40.4%<break/>2: 30.8%<break/>3: 28.8%</td><td>1: 47.0%<break/>2: 19.3%<break/>3: 33.7%</td><td>1: 15.2%<break/>2: 46.0%<break/>3: 38.8%</td></tr><tr><td>&#x000a0;TAR<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td>0: 73.2%<break/>1: 26.8%</td><td>0: 41.3%<break/>1: 58.7%</td><td>0: 20.2%<break/>1: 79.8%</td><td>0: 37.3%<break/>1: 62.7%</td><td>0: 31.7%<break/>1: 68.3%</td></tr></tbody></table><table-wrap-foot><fn><p>CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine; ALB: albumin; FRE: Dosage Frequency; FT: PD targets, 50/70/100% fT&#x000a0;&#x0003e;&#x000a0;MIC, 1,2,3 represent 50%, 70% and 100% respectively; TAR: prediction target, concentration meets the standard as 1, does not meet the standard as&#x000a0;0.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fna"><label>a</label><p id="ntpara0020">The results were shown in median (range).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnb"><label>b</label><p id="ntpara0025">The results are presented as proportions for each category.</p></fn></table-wrap-foot></table-wrap></p><p id="p0150">Amoxicillin was administered to 157 patients, with 73.2% of the patients having real-world concentrations below the target (i.e., TAR &#x0003c; 0). Among the patients, 63.7% (n&#x000a0;=&#x000a0;100) were administered a Q12h dosing regimen with a median (range) dose of 23.7 (16.7&#x02013;32.1) mg/kg. Ceftazidime was administered to 138 patients, with 41.3% of the patients having real-world concentrations below the target (i.e., TAR &#x0003c; 0). Among the patients, 60.1% (n&#x000a0;=&#x000a0;100) were administered with a Q12h dosing regimen, with a median (range) dose of 29.1 (21.2&#x02013;80.0) mg/kg. Cefotaxime was administered to 104 patients, with 20.2% of the patients having real-world concentrations below the target (i.e., TAR &#x0003c; 0). Among the patients, 52.9% (n&#x000a0;=&#x000a0;100) were administered with a Q12h dosing regimen, with a median (range) dose of 49.5 (31.7&#x02013;105.0) mg/kg. Meropenem was administered to 83 patients, with 37.3% of the patients having real-world concentrations below the target (i.e., TAR &#x0003c; 0). Among the patients, 28.9% (n&#x000a0;=&#x000a0;100) were administered with a Q12h dosing regimen, with a median (range) dose of 19.8 (8.80&#x02013;85.7) mg/kg. Latamoxef was administered to 139 patients, with 31.7% of the patients having real-world concentrations below the target (i.e., TAR &#x0003c; 0). Among these patients, 69.8% (n&#x000a0;=&#x000a0;100) received a Q12h dosing regimen, with a median (range) dose of 30.0 (24.0&#x02013;56.1) mg/kg.</p><p id="p0155">For the CDSS, the accuracies were 96.2%, 84.1%, 90.4%, 83.1%, and 88.5% for amoxicillin ceftazidime, cefotaxime, meropenem, and latamoxef, respectively. The precisions were 82.4%, 93.8%, 86.5%, 93.4%, and 85.5%, respectively. The recalls were 82.4%, 95.8%, 86.5%, 89.5%, and 87.7%, respectively. The F1-Scores were 82.4%, 94.8%, 86.5%, 91.4%, and 86.6%, respectively.</p></sec><sec id="sec3.2.2"><title>Predictive performance of CDSS compared to the PopPK model</title><p id="p0160">For the PopPK model, the accuracies were 87.9%, 82.6%, 77.9%, 73.5%, and 78.4% for amoxicillin ceftazidime, cefotaxime, meropenem, and latamoxef, respectively. The precisions were 40.0%, 85.2%, 90.5%, 89.5% and 90.0%, respectively. The recalls were 23.5%, 85.2%, 80.7%, 65.4% and 76.8%, respectively. The F1-Scores were 29.6%, 85.2%, 85.4%, 75.6% and 83.0%, respectively.</p><p id="p0165">Using the CDSS, the accuracy improved by 9.4%, 1.8%, 16.1%, 13.1% and 12.9% for amoxicillin ceftazidime, cefotaxime, meropenem, and latamoxef, respectively, compared to the PopPK model. Overall accuracy improved by 10.7%. The overall prediction precision, recall, and F1-Score of the CDSS (ML model) improved by 22.1%, 64.2, and 43.1%, respectively. The detailed validation results were shown in <xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>.</p></sec></sec><sec id="sec3.3"><title>CDSS-based dose optimization</title><p id="p0170">The guidelines recommend doses of beta-lactam antibiotics for anti-infective therapy in neonates, as shown in <xref rid="tbl6" ref-type="table">Table&#x000a0;6</xref> (excluding indications for neonatal meningitis). Using the CDSS-optimized dosing regimen, the PTA for amoxicillin, ceftazidime, cefotaxime, meropenem, and latamoxef increased by 113.5%, 113.5%, 25.3%, 30.7%, and 8.1%, respectively, relative to the guideline-recommended dosing regimen (mean PTA). The PTAs for the CDSS-optimized dose regimen and the guideline-recommended dose regimen in neonatal patients were shown in <xref rid="tbl7" ref-type="table">Table&#x000a0;7</xref>.<table-wrap position="float" id="tbl6"><label>Table&#x000a0;6</label><caption><p>The guidelines recommend doses of beta-lactam antibiotics for anti-infective therapy in neonates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Amoxicillin</th><th>Ceftazidime</th><th>Cefotaxime</th><th>Meropenem</th><th>Latamoxef</th></tr></thead><tbody><tr><td>BLUE</td><td>PNA &#x0003c;7 day:<break/>30&#x02013;60&#x000a0;mg/kg Q12h<break/>PNA &#x02265; 7 day:<break/>30&#x02013;60&#x000a0;mg/kg Q8h</td><td>PNA&#x0003c;7 day:<break/>25&#x000a0;mg/kg Q12h<break/>PNA &#x0223c; 7&#x02013;21 day:<break/>25&#x000a0;mg/kg Q8h<break/>PNA &#x0223c;21&#x02013;28 day:<break/>25&#x000a0;mg/kg Q6h</td><td>PNA &#x0003c;7 day:<break/>25&#x02013;50&#x000a0;mg/kg Q24h<break/>PNA &#x0223c; 7&#x02013;21 day:<break/>25&#x02013;50&#x000a0;mg/kg Q12h<break/>PNA &#x02265; 21 day:<break/>25&#x02013;50&#x000a0;mg/kg Q8h</td><td>PNA &#x0003c;7 day:<break/>40&#x000a0;mg/kg Q12h<break/>PNA &#x02265; 7 day:<break/>40&#x000a0;mg/kg Q8h</td><td>/</td></tr><tr><td>BNFC</td><td>PNA &#x0003c;7 day:<break/>30&#x02013;50&#x000a0;mg/kg Q12h<break/>PNA &#x02265; 7 day:<break/>30&#x02013;50&#x000a0;mg/kg Q8h</td><td>PNA&#x0003c;7 day:<break/>25&#x000a0;mg/kg Q12h<break/>PNA &#x0223c; 7&#x02013;21 day:<break/>25&#x000a0;mg/kg Q8h<break/>PNA &#x0223c;21&#x02013;28 day:<break/>25&#x000a0;mg/kg Q6h</td><td>PNA &#x0003c;7 day:<break/>25&#x000a0;mg/kg Q24h<break/>PNA &#x0223c; 7&#x02013;21:<break/>25&#x000a0;mg/kg Q12h<break/>PNA &#x0223c;21&#x02013;28 day:<break/>25&#x000a0;mg/kg Q8h</td><td>PNA &#x0003c;7 day:<break/>20&#x000a0;mg/kg Q12h<break/>PNA &#x02265; 7 day:<break/>20&#x000a0;mg/kg Q8h</td><td>/</td></tr><tr><td>FDAL</td><td>30&#x000a0;mg/kg/day Q12h</td><td>PNA &#x0003c;7 day:<break/>50&#x000a0;mg/kg Q12h<break/>PNA &#x0223c;7&#x02013;28 day:<break/>50&#x000a0;mg/kg Q8h</td><td>30&#x000a0;mg/kg Q12h</td><td>/</td><td>40&#x02013;80&#x000a0;mg/kg/day<break/>Q6&#x02013;12&#x000a0;h<xref rid="tbl6fna" ref-type="table-fn">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="tbl6fna"><label>a</label><p id="ntpara0030">The relevant dose was not retrieved and was substituted using the Chinese drug instruction dose. BLUE: The Blue Book; BNFC: British National Formulary for Children; FDAL: Food and Drug Administration Label; PNA: postnatal age.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl7"><label>Table&#x000a0;7</label><caption><p>The probability of target concentration attainment of CDSS-optimized dose and guideline-recommended dose.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Amoxicillin</th><th>Ceftazidime</th><th>Cefotaxime</th><th>Meropenem</th><th>Latamoxef</th></tr></thead><tbody><tr><td>CDSS (%)</td><td align="char">77.5</td><td align="char">92.0</td><td align="char">77.9</td><td>77.1</td><td>82.7</td></tr><tr><td>BLUE (%)</td><td align="char">52.9</td><td align="char">55.5</td><td align="char">56.7</td><td>/</td><td>/</td></tr><tr><td>BNFC (%)</td><td align="char">47.1</td><td align="char">29.0</td><td align="char">56.7</td><td>59.0</td><td>/</td></tr><tr><td>FDAL (%)</td><td align="char">8.8</td><td align="char">44.9</td><td align="char">73.1</td><td>/</td><td>76.5</td></tr><tr><td>MEANG (%)</td><td align="char">36.3</td><td align="char">43.1</td><td align="char">62.2</td><td>59.0</td><td>76.5</td></tr></tbody></table><table-wrap-foot><fn><p>CDSS: clinical decision-support system; BLUE: The Blue Book; BNFC: British National Formulary for Children; FDAL: Food and Drug Administration Label; MEANG: Mean values for the guideline-recommended doses.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.4"><title>Software and website construction</title><p id="p0175">The CDSS was converted into software and a website for application in clinical practice. The CDSS software and website were designed to operate in a mode that could automatically invoke updates, thereby enabling dose prediction without the need for multiple repeated attempts. In other words, when the CDSS predicts a current dose failure, it not only notifies the user of the inadequacy but also automatically searches for the optimal dose (by setting the dose range and single-step incremental doses). The detailed information and display windows were shown in <xref rid="appsec1" ref-type="sec">Supplementary Material S2</xref>.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0180">To our knowledge, this is the first study to evaluate whether the optimal dose of &#x003b2;-lactam antibiotics in neonatal sepsis can be predicted using an ML-based CDSS. In recent years, ML analytics have become increasingly popular for individualized treatment, with application flexibility and convenience being its main advantages.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> However, building an accurate and precise model that can handle the intricacy of the interactions between features and the output value calls for large datasets. This restricts their ability to advance in the neonatal field. The neonatal &#x003b2;-lactam antibiotics application field faces a double challenge, as the actual %fT&#x000a0;&#x0003e;&#x000a0;MIC cannot be measured directly. A theoretical approach is to simulate datasets, build ML models based on these simulations, and validate them using external data.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p><p id="p0185">According to the published ML recommendations, our study is of high quality, having completed validation based on real-world data.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> The PopPK model utilizes a compartment structure as its framework and incorporates fixed and random effects. ML is a data-driven approach that eliminates mechanistic assumptions. The objective of ML models is accuracy. Although the ML model in this study was constructed based on simulated data (generated by the PopPK model), because of different mechanisms, the ML model may perform differently when confronted with new data and situations compared with the PopPK model.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> As shown by the real-world data validation results, the overall prediction accuracy, precision, recall, and F1-Score of the CDSS improved by 10.7%, 22.1%, 64.2, and 43.1%, respectively.</p><p id="p0190">The PD target of time-dependent &#x003b2;-lactam antibiotics is the %fT&#x000a0;&#x0003e;&#x000a0;MIC. A dosing interval of at least 40&#x02013;50% fT&#x000a0;&#x0003e;&#x000a0;MIC was accepted for adults. To prevent the development of antibiotic resistance and ensure effectiveness, neonates should be considered in an immunocompromised state and require a higher %fT&#x000a0;&#x0003e;&#x000a0;MIC. However, the specific target PD value in neonates remains controversial. Various PD targets range from 40% fT&#x000a0;&#x0003e;&#x000a0;MIC up to 100% fT&#x000a0;&#x0003e;&#x000a0;4&#x02013;5 x MIC in most neonatal studies.<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref> There is no generally accepted PD target because it is usually defined based on expert opinions rather than theoretical arguments or in&#x000a0;vitro data.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> Thus, in this study, various PD targets, 50%, 70%, and 100%, which were the three most common PD targets, were selected for subsequent ML model training and prediction. This made the final CDSS more flexible and useful for clinical applications.</p><p id="p0195">The identification of infectious pathogens and their corresponding MICs are crucial for selecting appropriate antibiotic therapies. However, because it is difficult to obtain positive culture and antimicrobial susceptibility results for bacteria in newborns,<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> empiric therapy is widely used to treat neonatal infectious diseases without information about the pathogens. In this study, according to national and international references, we determined the MIC values of the five most common pathogens of neonatal sepsis and selected one of each to cover all pathogens.</p><p id="p0200">Several studies have utilized ML to predict antibiotic dosages. For example, Codde C et&#x000a0;al. successfully predicted the steady-state AUC of daptomycin by incorporating peak concentrations, trough concentrations (C<sub>0</sub>), and other covariates for dose adjustments.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Similarly, Ma et&#x000a0;al. predicted trough concentrations of teicoplanin to optimize dosing regimens.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> Various studies, such as those by Bououda M et&#x000a0;al.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> and Huang et&#x000a0;al.,<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> have focused on predicting steady-state AUC or trough concentrations of vancomycin. However, these studies primarily concentrate on adult populations, with limited attention to neonatal groups. Clinically, these studies are mainly used for dose optimization based on existing drug concentrations, with minimal research on initial dosing or comprehensive dose optimization throughout treatment. Mechanistically, existing ML studies mainly focus on concentration-dependent antibiotics and recommend doses based on AUC/C<sub>0</sub> predictions, neglecting research on time-dependent antibiotics that require assessing the duration free drug concentrations remain above the MIC.</p><p id="p0205">The high scores on the test set are attributed to the fact that our predictive model was built based on simulated data, whereas the external validation data were derived from the real world, making its conditions more complex. We understand and acknowledge that the validation set results may show a decrease compared to the test set, which is expected because as the validation set better simulates the complexity and uncertainty of the real world. When the model is applied in clinical settings, continuous incorporation of real data will lead to ongoing improvements, allowing the model to better adhere to the principles of &#x0201c;learning and confirming&#x0201d;. Overall, although there are differences between the predictive results of the validation set and test sets, they remain satisfactory and outperform traditional or alternative predictive methods.</p><p id="p0210">The CDSS showed acceptable prediction performance. Using real-world data, all five drugs had a prediction accuracy of 80% or more. Initially, the CDSS has the potential to treat new neonatal patients. The clinician entered the target drug, the characteristics of the neonate (e.g., age, weight, biochemical information), and the PD target (50%, 70%, or 100% fT&#x000a0;&#x0003e;&#x000a0;MIC) into each module of the system, and the system automatically determines whether the concentration at the planned dose regimen would reach the target (individual concentrations above the default MIC). The clinician selects an appropriate initial dosing regimen based on the predicted results. Based on the clinical outcomes of the current dosing regimen, physicians may choose to implement further dose adjustments based on the CDSS. If the treatment is ineffective (excluding cases of bacterial resistance, in which case it is recommended to change the drug), the clinician can determine a new dose by adjusting the three modules: patient, dosage, and PD target; if the treatment is effective, the current dose is maintained. The application scenario for the CDSS was shown in <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>.<fig id="fig4"><label>Fig.&#x000a0;4</label><caption><p>Schematic diagram to illustrate how the clinical decision support system would be applied in clinical practice. CDSS: Clinical Decision Support System; PD: pharmacodynamics; CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0215">Limitations of the Study. Covariates related to disease status and concomitant medications were not included in this study. The clinical value of this dose selection system needs to be validated in clinical practice. The clinical dose selection system requires continual refinement in clinical practice to adhere to the principles of &#x0201c;learning and confirming.&#x0201d;</p><sec id="sec4.1"><title>Conclusions</title><p id="p0220">An ML-based clinical decision support system was successfully constructed to assist clinicians in making optimal dose decisions for &#x003b2;-lactam antibiotics to treat neonatal sepsis.</p></sec></sec><sec id="sec5"><title>Contributors</title><p id="p0225">Bo-Hao Tang wrote the manuscript; Wei Zhao designed the research; Bu-Fan Yao, Yue-E Wu, Guo-Xiang Hao, Wei Zhang, Xin-Fang Zhang, Shu-Meng Fu, Yi Zheng, Yue Zhou and John van den Anker performed the research; Bo-Hao Tang, Yue-E Wu, De-Qing Sun, Gang Liu and Guo-Xiang Hao analyzed the data. Bo-Hao Tang and Bu-Fan Yao directly accessed and verified the underlying data reported in the manuscript. Bo-Hao Tang and Wei Zhao were responsible for the decision to submit the manuscript. All authors read and approved the final version of the manuscript, and ensure it is the case.</p></sec><sec id="sec6"><title>Data sharing statement</title><p id="p0230">The dataset collected for this study will be made available to others upon reasonable request. These data will be available upon publication of this study. Data will be made available through the email address of the corresponding author. Requests for data access must be approved by the relevant ethics boards and data custodians. Access will be granted based on a research proposal.</p></sec><sec sec-type="COI-statement"><title>Declaration of interests</title><p id="p0235">All authors declare that they have no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Odabasi</surname><given-names>I.O.</given-names></name><name><surname>Bulbul</surname><given-names>A.</given-names></name></person-group><article-title>Neonatal sepsis</article-title><source>Sisli Etfal Hastan Tip Bul</source><volume>54</volume><issue>2</issue><year>2020</year><fpage>142</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">32617051</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Youngster</surname><given-names>I.</given-names></name><name><surname>Avorn</surname><given-names>J.</given-names></name><name><surname>Belleudi</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Antibiotic use in children - a cross-national analysis of 6 countries</article-title><source>J&#x000a0;Pediatr</source><volume>182</volume><year>2017</year><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">28012694</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>de Hoog</surname><given-names>M.</given-names></name><name><surname>Mouton</surname><given-names>J.W.</given-names></name><name><surname>van den Anker</surname><given-names>J.N.</given-names></name></person-group><article-title>New dosing strategies for antibacterial agents in the neonate</article-title><source>Semin Fetal Neonatal Med</source><volume>10</volume><issue>2</issue><year>2005</year><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15701583</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Kumar</surname><given-names>S.S.</given-names></name><name><surname>Sherwin</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Renal clearance in newborns and infants: predictive performance of population-based modeling for drug development</article-title><source>Clin Pharmacol Ther</source><volume>105</volume><issue>6</issue><year>2019</year><fpage>1462</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">30565653</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>D.F.</given-names></name><name><surname>Tang</surname><given-names>B.H.</given-names></name><etal/></person-group><article-title>Clinical utility of a model-based amoxicillin dosage regimen in neonates with early-onset sepsis</article-title><source>Br J Clin Pharmacol</source><volume>88</volume><issue>11</issue><year>2022</year><fpage>4950</fpage><lpage>4955</lpage><pub-id pub-id-type="pmid">36057912</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>H.L.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>76</volume><issue>3</issue><year>2020</year><fpage>699</fpage><lpage>709</lpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Hou</surname><given-names>S.S.</given-names></name><name><surname>Fang</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Clinical utiliy of a model-based piperacillin dose in neonates with early-onset sepsis</article-title><source>Br J Clin Pharmacol</source><volume>88</volume><issue>3</issue><year>2022</year><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">34450681</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>B.F.</given-names></name><name><surname>Kou</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>H.Y.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name></person-group><article-title>Developmental population pharmacokinetics and dosing optimization of cefepime in neonates and young infants</article-title><source>Front Pharmacol</source><volume>11</volume><year>2020</year><fpage>14</fpage><pub-id pub-id-type="pmid">32116695</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Kou</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Developmental population pharmacokinetics-pharmacodynamics of meropenem in Chinese neonates and young infants: dosing recommendations for late-onset sepsis</article-title><source>Children</source><volume>9</volume><issue>12</issue><year>2022</year><fpage>1998</fpage><pub-id pub-id-type="pmid">36553441</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.K.</given-names></name><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Optimal dosing of ceftriaxone in infants based on a developmental population pharmacokinetic-pharmacodynamic analysis</article-title><source>Antimicrob Agents Chemother</source><volume>64</volume><issue>11</issue><year>2020</year><object-id pub-id-type="publisher-id">e01412-20</object-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Jacqz-Aigrain</surname><given-names>E.</given-names></name><name><surname>Leroux</surname><given-names>S.</given-names></name><name><surname>Thomson</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>74</volume><issue>8</issue><year>2019</year><fpage>2128</fpage><lpage>2138</lpage><pub-id pub-id-type="pmid">31049551</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>B.H.</given-names></name><name><surname>Zhang</surname><given-names>J.Y.</given-names></name><name><surname>Allegaert</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Use of machine learning for dosage individualization of vancomycin in neonates</article-title><source>Clin Pharmacokinet</source><volume>62</volume><issue>8</issue><year>2023</year><fpage>1105</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">37300630</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Z.L.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>77</volume><issue>8</issue><year>2022</year><fpage>2238</fpage><lpage>2244</lpage><pub-id pub-id-type="pmid">35662337</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Z.R.</given-names></name><name><surname>Chen</surname><given-names>X.K.</given-names></name><name><surname>Tian</surname><given-names>L.Y.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and dosing optimization of ceftazidime in infants</article-title><source>Antimicrob Agents Chemother</source><volume>62</volume><issue>4</issue><year>2018</year><object-id pub-id-type="publisher-id">e02486-17</object-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Carmine</surname><given-names>A.A.</given-names></name><name><surname>Brogden</surname><given-names>R.N.</given-names></name><name><surname>Heel</surname><given-names>R.C.</given-names></name><name><surname>Speight</surname><given-names>T.M.</given-names></name><name><surname>Avery</surname><given-names>G.S.</given-names></name></person-group><article-title>Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use</article-title><source>Drugs</source><volume>25</volume><issue>3</issue><year>1983</year><fpage>223</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">6303743</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>Y.S.</given-names></name><name><surname>Chung</surname><given-names>K.C.</given-names></name><name><surname>Gill</surname><given-names>M.A.</given-names></name></person-group><article-title>Pharmacokinetics of meropenem in animals, healthy volunteers, and patients</article-title><source>Clin Infect Dis</source><volume>24</volume><issue>Suppl 2</issue><year>1997</year><fpage>S249</fpage><lpage>S255</lpage><pub-id pub-id-type="pmid">9126700</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Carmine</surname><given-names>A.A.</given-names></name><name><surname>Brogden</surname><given-names>R.N.</given-names></name><name><surname>Heel</surname><given-names>R.C.</given-names></name><name><surname>Romankiewicz</surname><given-names>J.A.</given-names></name><name><surname>Speight</surname><given-names>T.M.</given-names></name><name><surname>Avery</surname><given-names>G.S.</given-names></name></person-group><article-title>Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use</article-title><source>Drugs</source><volume>26</volume><issue>4</issue><year>1983</year><fpage>279</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">6354685</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>van den Anker</surname><given-names>J.N.</given-names></name></person-group><article-title>Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates</article-title><source>Ther Drug Monit</source><volume>28</volume><issue>6</issue><year>2006</year><fpage>816</fpage><comment>author reply -7</comment><pub-id pub-id-type="pmid">17164701</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Munshi</surname><given-names>R.</given-names></name><name><surname>Talele</surname><given-names>G.</given-names></name><name><surname>Shah</surname><given-names>R.</given-names></name></person-group><article-title>In-vitro evaluation of antimicrobial activities of Escherichia coli, Klebsiella pneumoniae, Salmonella typhi, Neisseria gonorrhoeae, and Candida albicans nosodes</article-title><source>Homeopathy</source><volume>111</volume><issue>1</issue><year>2022</year><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">34020481</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R.N.</given-names></name><name><surname>Barry</surname><given-names>A.L.</given-names></name><name><surname>Thornsberry</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>8</volume><issue>Suppl B</issue><year>1981</year><fpage>187</fpage><lpage>211</lpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>S.J.F.</given-names></name><name><surname>Upadhyay</surname><given-names>P.J.</given-names></name><name><surname>Hagedoorn</surname><given-names>N.N.</given-names></name><etal/></person-group><article-title>Current ceftriaxone dose recommendations are adequate for most critically ill children: results of a population pharmacokinetic modeling and simulation study</article-title><source>Clin Pharmacokinet</source><volume>60</volume><issue>10</issue><year>2021</year><fpage>1361</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">34036552</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Leroux</surname><given-names>S.</given-names></name><name><surname>Roue</surname><given-names>J.M.</given-names></name><name><surname>Gouyon</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>A&#x000a0;population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants</article-title><source>Antimicrob Agents Chemother</source><volume>60</volume><issue>11</issue><year>2016</year><fpage>6626</fpage><lpage>6634</lpage><pub-id pub-id-type="pmid">27572399</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Joly-Guillou</surname><given-names>M.L.</given-names></name><name><surname>Kempf</surname><given-names>M.</given-names></name><name><surname>Cavallo</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Comparative in&#x000a0;vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study</article-title><source>BMC Infect Dis</source><volume>10</volume><year>2010</year><fpage>72</fpage><pub-id pub-id-type="pmid">20298555</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>J.J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>[The activity of moxalactam against Enterobacteriaceae and anaerobia in&#x000a0;vitro]</article-title><source>Zhonghua Yixue Zazhi</source><volume>96</volume><issue>18</issue><year>2016</year><fpage>1459</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">27266357</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>S.</given-names></name><name><surname>Simon</surname><given-names>R.</given-names></name></person-group><article-title>Bias in error estimation when using cross-validation for model selection</article-title><source>BMC Bioinf</source><volume>7</volume><year>2006</year><fpage>91</fpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Krstajic</surname><given-names>D.</given-names></name><name><surname>Buturovic</surname><given-names>L.J.</given-names></name><name><surname>Leahy</surname><given-names>D.E.</given-names></name><name><surname>Thomas</surname><given-names>S.</given-names></name></person-group><article-title>Cross-validation pitfalls when selecting and assessing regression and classification models</article-title><source>J&#x000a0;Cheminformatics</source><volume>6</volume><year>2014</year><fpage>10</fpage></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="other" id="sref27"><person-group person-group-type="author"><name><surname>Dorogush</surname><given-names>A.V.</given-names></name><name><surname>Ershov</surname><given-names>V.</given-names></name><name><surname>Gulin</surname><given-names>A.</given-names></name></person-group><article-title>CatBoost: gradient boosting with categorical features support 2018</article-title><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/pdf/1810.11363.pdf" id="intref0015">https://arxiv.org/pdf/1810.11363.pdf</ext-link></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="book" id="sref28"><person-group person-group-type="editor"><name><surname>Prokhorenkova</surname><given-names>L.</given-names></name><name><surname>Gusev</surname><given-names>G.</given-names></name><name><surname>Vorobev</surname><given-names>A.</given-names></name><name><surname>Dorogush</surname><given-names>A.V.</given-names></name><name><surname>Gulin</surname><given-names>A.</given-names></name></person-group><source>CatBoost: unbiased boosting with categorical features</source><year>2017</year></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Ogami</surname><given-names>C.</given-names></name><name><surname>Tsuji</surname><given-names>Y.</given-names></name><name><surname>Seki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>An artificial neural network-pharmacokinetic model and its interpretation using Shapley additive explanations</article-title><source>CPT Pharmacometr Syst Pharmacol</source><volume>10</volume><issue>7</issue><year>2021</year><fpage>760</fpage><lpage>768</lpage></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="book" id="sref30"><person-group person-group-type="author"><name><surname>Sharland</surname><given-names>M.</given-names></name></person-group><source>Manual of childhood Infections: the blue Book</source><year>2016</year></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="book" id="sref31"><person-group person-group-type="author"><name><surname>Committee</surname><given-names>JF.</given-names></name></person-group><source>British national formulary for children 2014-2015</source><year>2014</year></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Guilhaumou</surname><given-names>R.</given-names></name><name><surname>Benaboud</surname><given-names>S.</given-names></name><name><surname>Bennis</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d'Anesthesie et Reanimation-SFAR)</article-title><source>Crit Care</source><volume>23</volume><issue>1</issue><year>2019</year><fpage>104</fpage><pub-id pub-id-type="pmid">30925922</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: dosing optimization for neonatal sepsis</article-title><source>Eur J Pharm Sci</source><volume>163</volume><year>2021</year><object-id pub-id-type="publisher-id">105868</object-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>P.B.</given-names></name><name><surname>Cohen-Wolkowiez</surname><given-names>M.</given-names></name><name><surname>Castro</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections</article-title><source>Pediatr Infect Dis J</source><volume>30</volume><issue>10</issue><year>2011</year><fpage>844</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">21829139</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>H.</given-names></name><name><surname>Kou</surname><given-names>C.</given-names></name><name><surname>Qi</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants</article-title><source>Int J Antimicrob Agents</source><volume>53</volume><issue>3</issue><year>2019</year><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">30472290</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>B.H.</given-names></name><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Kou</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants</article-title><source>Antimicrob Agents Chemother</source><volume>63</volume><issue>2</issue><year>2019</year><object-id pub-id-type="publisher-id">e02336-18</object-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Bizzarro</surname><given-names>M.J.</given-names></name><name><surname>Raskind</surname><given-names>C.</given-names></name><name><surname>Baltimore</surname><given-names>R.S.</given-names></name><name><surname>Gallagher</surname><given-names>P.G.</given-names></name></person-group><article-title>Seventy-five years of neonatal sepsis at Yale: 1928-2003</article-title><source>Pediatrics</source><volume>116</volume><issue>3</issue><year>2005</year><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">16140698</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Vergnano</surname><given-names>S.</given-names></name><name><surname>Menson</surname><given-names>E.</given-names></name><name><surname>Kennea</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Neonatal infections in England: the NeonIN surveillance network</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><volume>96</volume><issue>1</issue><year>2011</year><fpage>F9</fpage><lpage>F14</lpage><pub-id pub-id-type="pmid">20876594</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>B.J.</given-names></name><name><surname>Hansen</surname><given-names>N.I.</given-names></name><name><surname>Sanchez</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues</article-title><source>Pediatrics</source><volume>127</volume><issue>5</issue><year>2011</year><fpage>817</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">21518717</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Muller-Pebody</surname><given-names>B.</given-names></name><name><surname>Johnson</surname><given-names>A.P.</given-names></name><name><surname>Heath</surname><given-names>P.T.</given-names></name><etal/></person-group><article-title>Empirical treatment of neonatal sepsis: are the current guidelines adequate?</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><volume>96</volume><issue>1</issue><year>2011</year><fpage>F4</fpage><lpage>F8</lpage><pub-id pub-id-type="pmid">20584804</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Resch</surname><given-names>B.</given-names></name><name><surname>B</surname><given-names>R.</given-names></name><name><surname>N</surname><given-names>H.</given-names></name></person-group><article-title>Comparison between pathogen associated laboratory and clinical parameters in early-onset sepsis of the newborn</article-title><source>Open Microbiol J</source><volume>10</volume><year>2016</year><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">27478518</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="book" id="sref42"><person-group person-group-type="author"><name><surname>Li-yuan</surname><given-names>G.</given-names></name></person-group><part-title>Literature research on the pathogen of early-onset sepsis in mainland China</part-title><year>2018</year><publisher-name>CNKI: Chongqing Medical University</publisher-name></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.P.</given-names></name><name><surname>Zhu</surname><given-names>Y.X.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Analysis of the distribution of late-onset sepsis pathogens and the influence factors of late-onset sepsis on very low and extremely low birth weight infants</article-title><source>Chinese J Gen Pract</source><volume>16</volume><issue>11</issue><year>2018</year><fpage>3</fpage></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.L.</given-names></name><name><surname>Qin</surname><given-names>X.L.</given-names></name><etal/></person-group><article-title>Distribution and drug sensitivity analysis of pathogens isolated from early &#x0ff0d; onset and late &#x0ff0d; onset neonatal sepsis</article-title><source>Chin J Health Lab Technol</source><volume>29</volume><issue>7</issue><year>2019</year><fpage>3</fpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.G.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Analysis on distribution and drug resistance of clinical pathogens of neonatal septicemia and its treatment strategies</article-title><source>Anti Infect Pharm</source><volume>16</volume><issue>4</issue><year>2019</year></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Wei-xin</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical characteristics and pathogenic bacteria of early-onset and late-onset neonatal sepsis</article-title><source>J&#x000a0;Guangdong Med Univ</source><volume>35</volume><year>2015</year></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.X.</given-names></name><name><surname>Jing</surname><given-names>W.L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical characteristics and pathogens of early and late neonatal sepsis analysis</article-title><source>Modern Instr Med Treat</source><volume>22</volume><year>2016</year></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Woillard</surname><given-names>J.B.</given-names></name><name><surname>Labriffe</surname><given-names>M.</given-names></name><name><surname>Debord</surname><given-names>J.</given-names></name><name><surname>Marquet</surname><given-names>P.</given-names></name></person-group><article-title>Tacrolimus exposure prediction using machine learning</article-title><source>Clin Pharmacol Ther</source><volume>110</volume><issue>2</issue><year>2021</year><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">33253425</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>B.H.</given-names></name><name><surname>Guan</surname><given-names>Z.</given-names></name><name><surname>Allegaert</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Drug clearance in neonates: a combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction</article-title><source>Clin Pharmacokinet</source><volume>60</volume><issue>11</issue><year>2021</year><fpage>1435</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">34041714</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.Y.</given-names></name><name><surname>Tang</surname><given-names>B.H.</given-names></name><name><surname>Wu</surname><given-names>Y.E.</given-names></name><etal/></person-group><article-title>Machine learning: a new approach for dose individualization</article-title><source>Clin Pharmacol Ther</source><volume>115</volume><issue>4</issue><year>2023</year><fpage>727</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">37713106</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Pullen</surname><given-names>J.</given-names></name><name><surname>Driessen</surname><given-names>M.</given-names></name><name><surname>Stolk</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Amoxicillin pharmacokinetics in (preterm) infants aged 10 to 52 days: effect of postnatal age</article-title><source>Ther Drug Monit</source><volume>29</volume><issue>3</issue><year>2007</year><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">17529898</pub-id>
</element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Pullen</surname><given-names>J.</given-names></name><name><surname>Stolk</surname><given-names>L.M.</given-names></name><name><surname>Nieman</surname><given-names>F.H.</given-names></name><name><surname>Degraeuwe</surname><given-names>P.L.</given-names></name><name><surname>van Tiel</surname><given-names>F.H.</given-names></name><name><surname>Zimmermann</surname><given-names>L.J.</given-names></name></person-group><article-title>Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates</article-title><source>Ther Drug Monit</source><volume>28</volume><issue>2</issue><year>2006</year><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">16628135</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>De Cock</surname><given-names>R.F.</given-names></name><name><surname>Smits</surname><given-names>A.</given-names></name><name><surname>Allegaert</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates</article-title><source>J&#x000a0;Antimicrob Chemother</source><volume>69</volume><issue>5</issue><year>2014</year><fpage>1330</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">24492261</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Z.H.</given-names></name><name><surname>Wu</surname><given-names>Y.E.</given-names></name><name><surname>Lv</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Optimal dose of cefotaxime in neonates with early-onset sepsis: a developmental pharmacokinetic model-based evaluation</article-title><source>Front Pharmacol</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">916253</object-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>A.H.</given-names></name><name><surname>Wyble</surname><given-names>L.E.</given-names></name><name><surname>Gal</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis</article-title><source>Antimicrob Agents Chemother</source><volume>38</volume><issue>9</issue><year>1994</year><fpage>2024</fpage><lpage>2028</lpage><pub-id pub-id-type="pmid">7811013</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Adrianzen Vargas</surname><given-names>M.R.</given-names></name><name><surname>Danton</surname><given-names>M.H.</given-names></name><name><surname>Javaid</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant cardiopulmonary bypass surgery</article-title><source>Eur J Cardio Thorac Surg</source><volume>25</volume><issue>2</issue><year>2004</year><fpage>256</fpage><lpage>260</lpage></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>J.A.</given-names></name><name><surname>Paul</surname><given-names>S.K.</given-names></name><name><surname>Akova</surname><given-names>M.</given-names></name><etal/></person-group><article-title>DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?</article-title><source>Clin Infect Dis</source><volume>58</volume><issue>8</issue><year>2014</year><fpage>1072</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">24429437</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Scharf</surname><given-names>C.</given-names></name><name><surname>Liebchen</surname><given-names>U.</given-names></name><name><surname>Paal</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome</article-title><source>J&#x000a0;Intensive Care</source><volume>8</volume><issue>1</issue><year>2020</year><fpage>86</fpage><pub-id pub-id-type="pmid">33292582</pub-id>
</element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>R.M.</given-names></name><name><surname>Muller-Pebody</surname><given-names>B.</given-names></name><name><surname>Planche</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Neonatal sepsis - many blood samples, few positive cultures: implications for improving antibiotic prescribing</article-title><source>Arch Dis Child Fetal</source><volume>97</volume><issue>6</issue><year>2012</year><fpage>F487</fpage><lpage>F488</lpage></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>P.C.</given-names></name><name><surname>Ma</surname><given-names>T.P.Y.</given-names></name><name><surname>Lam</surname><given-names>H.S.</given-names></name></person-group><article-title>The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis</article-title><source>Arch Dis Child Fetal</source><volume>100</volume><issue>5</issue><year>2015</year><fpage>F448</fpage><lpage>F452</lpage></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Codde</surname><given-names>C.</given-names></name><name><surname>Rivals</surname><given-names>F.</given-names></name><name><surname>Destere</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A&#x000a0;machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations</article-title><source>Antimicrob Agents Chemother</source><volume>68</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">e0141523</object-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Construction and interpretation of prediction model of teicoplanin trough concentration via machine learning</article-title><source>Front Med</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">808969</object-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Bououda</surname><given-names>M.</given-names></name><name><surname>Uster</surname><given-names>D.W.</given-names></name><name><surname>Sidorov</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A&#x000a0;machine learning approach to predict interdose vancomycin exposure</article-title><source>Pharm Res</source><volume>39</volume><issue>4</issue><year>2022</year><fpage>721</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">35411504</pub-id>
</element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Bu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An ensemble model for prediction of vancomycin trough concentrations in pediatric patients</article-title><source>Drug Des Dev Ther</source><volume>15</volume><year>2021</year><fpage>1549</fpage><lpage>1559</lpage></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Appendix ASupplementary data</title><p id="p0245">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary Material S1</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Supplementary Material S2</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0240">This work was supported by the <funding-source id="gs2">National Key Research and Development Program of China</funding-source> (<award-id award-type="grant" rid="gs2">2023YFC2706100</award-id>); <funding-source id="gs4">National Natural Science Foundation of China</funding-source> (<award-id award-type="grant" rid="gs4">82173897</award-id>); Distinguished Young and Middle-aged Scholar of Shandong University; Innovation and Development Joint Fund of Natural Science Foundation of Shandong Province (ZR2022LSW007) and <funding-source id="gs3">Natural Science Foundation of Shandong Province</funding-source> (<award-id award-type="grant" rid="gs3">ZR2022QH004</award-id>). Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0250">Supplementary data related to this article can be found at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ebiom.2024.105221" id="intref0010">https://doi.org/10.1016/j.ebiom.2024.105221</ext-link>.</p></fn></fn-group></back></article>